Letter Ahead of print
PubMed: 42464053 DOI: 10.1111/ijd.70592
Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force "Dermatology for Cancer Patients".
Int J Dermatol
Authors: Dimitra Koumaki, Ioannis-Alexios Koumprentziotis, Zoe Apalla, Vincent Sibaud, Michela Valeria Rita Starace, Luca Rapparini, Sonia Segura, Gloria Juan-Carpena, Mar Blanes-Martínez, Chrysa Oikonomou, Florentina Delli, Elena Sotiriou, Ander Mayor, Joaquín López Robles, Monika Arenbergerová, Vasiliki Nikolaou
Affiliations
- Dermatology Department, University Hospital of Heraklion, Heraklion, Greece.
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
- Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Department of Dermatology, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Dermatology, Alicante University General Hospital, Alicante, Spain.
- Dermatology Department, General University Hospital of Patra, Patra, Greece.
- First Dermatology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Servicio de Dermatología, Hospital Universitario La Paz, Madrid, Spain.
- Morales Meseguer University General Hospital, Murcia, Spain.
- Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
MeSH
Safety, Neoplasms, Immune Checkpoint Inhibitors, Psoriasis, Dermatology